Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 695

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 695
---
 a single, smaller ALS clinical trial in September 2022. However, a larger clinical trial failed to confirm the earlier findings, and the manufacturer of Relyvrio removed the drug from the market in 2024. •Tofersen (Qalsody) is given through a spinal injection to people with ALS who have been determined to have a mutation in the SOD1 gene. While the benefits of this drug are still under study, it may work by decreasing one of the markers of damage to neurons.

| Moore Financial Consulting |

Annex E-15

ALS Prevalence In The following table can be found data regarding the prevalence of ALS in the population of the US, Japan and the five European largest economies 1 2 3:

|          |     |             |     | Prevalence |     |        |
| Country  |     | Population1 |     |   per 100k |     |  Total |
| USA2     |     | 345,426,571 |     |       8.63 |     | 29,824 |
| Germany3 |     |  84,552,242 |     |       6.23 |     |  5,268 |
| France3  |     |  66,548,530 |     |       6.23 |     |  4,146 |
| UK3      |     |  69,138,192 |     |       4.03 |     |  2,786 |
| Spain3   |     |  47,910,526 |     |       6.89 |     |  3,301 |
| Italy3   |     |  59,342,867 |     |       7.85 |     |  4,658 |
| Japan3   |     | 123,753,041 |     |       7.96 |     |  9,851 |

Diabetes Diabetes is a chronic, metabolic disease characterized by elevated levels of blood glucose (or blood sugar), which leads over time to serious damage to the heart, blood vessels, eyes, kidneys and nerves. The most common is type 2 diabetes, usually in adults, which occurs when the body becomes resistant to insulin or doesn’t make enough insulin. In the past 3 decades the prevalence of type 2 diabetes has risen dramatically in countries of all income levels. Type 1 diabetes, once known as juvenile diabetes or insulin -dependent